Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 10/20 | 1.00 |
| ▸ | NOS2 | P35228 | 9/20 | 1.00 |
| ▸ | NOS3 | P29474 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | DDAH1 | O94760 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Methyl-D-Thiocitrulline SCHEMBL9114394 | 1.00 | NOS1 (1.00) | NOS1NOS2NOS3CYP2C19THPO | |
| Thiocitrulline SCHEMBL4406617 | 0.98 | NOS1 (0.97) | NOS1NOS2NOS3CYP2C19THPO | |
| Thiocitrulline SCHEMBL1320099 | 0.97 | NOS2 (0.94) | NOS1NOS2NOS3CYP2C19THPO | |
| SCHEMBL14486327 | 0.88 | NOS1 (0.78) | NOS1NOS2NOS3CYP2C19THPO | |
| SCHEMBL232480 | 0.83 | NOS1 (1.00) | NOS1NOS2NOS3CYP2C19THPO | |
| SCHEMBL9115404 | 0.83 | NOS1 (0.71) | NOS1NOS2NOS3CYP2C19THPO | |
| SCHEMBL9115420 | 0.82 | NOS1 (0.69) | NOS1NOS2NOS3CYP2C19THPO | |
| SCHEMBL29941582 | 0.81 | NOS1 (0.74) | NOS1NOS2NOS3CYP2C19THPO | |
| SCHEMBL9115754 | 0.81 | NOS1 (0.78) | NOS1NOS2NOS3CYP2C19THPO | |
| SCHEMBL9114350 | 0.81 | NOS1 (0.73) | NOS1NOS2NOS3CYP2C19THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2025-08-14 | — | — | US | claimed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-09-26 | — | — | US | claimed |
| CN-116685302-A | Topical compositions | 利勒格有限公司 | 2023-09-01 | — | — | CN | claimed |
| US-20230083417-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-16 | — | — | US | claimed |
| EP-4110396-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | Universiteit Maastricht (NL) | 2023-01-04 | — | — | EP | claimed |
| CN-115192564-A | Phenylalanine derivative, pharmaceutical composition and application of phenylalanine derivative and pharmaceutical composition in tumor treatment | 四川大学华西医院 | 2022-10-18 | — | — | CN | claimed |
| US-20180161376-A1 | COMPOSITIONS AND METHODS FOR NEURONAL DIFFERENTIATION OF CELLS | NORTHERN SYDNEY LOCAL HEALTH DISTRICT (AU) | 2018-06-14 | — | — | US | claimed |
| US-20180052161-A1 | BIOMARKERS FOR MALARIA DIAGNOSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2018-02-22 | — | — | US | claimed |
| EP-3230440-A1 | COMPOSITIONS AND METHODS FOR NEURONAL DIFFERENTIATION OF CELLS | Northern Sydney Local Health District (AU) | 2017-10-18 | — | — | EP | claimed |
| EP-1161235-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING ANGIOGENESIS | Angiogene Pharmaceuticals Ltd (GB) | 2001-12-12 | — | — | EP | claimed |
| WO-2001032216-A2 | PRODUCT COMPRISING AT LEAST A NO SYNTHASE INHIBITING SUBSTANCE ASSOCIATED WITH AT LEAST A PHOSPHOLIPASE A2 INHIBITING SUBSTANCE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-10 | — | — | WO | claimed |
| WO-2000059448-A2 | ASSOCIATION OF NO-SYNTHASE INHIBITOR(S) AND METABOLIC ANTIOXIDANT(S) | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-10-12 | — | — | WO | claimed |
| WO-2000048591-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING ANGIOGENESIS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-08-24 | — | — | WO | claimed |
| US-6043268-A | Agent for treatment of viral infections | Maeda, Hiroshi (JP) | 2000-03-28 | — | — | US | claimed |
| EP-0939654-A1 | ASSOCIATION OF NO SYNTASE INHIBITORS WITH TRAPPERS OF OXYGEN REACTIVE FORMS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-09-08 | — | — | EP | claimed |
| WO-1998009653-A1 | ASSOCIATION OF NO SYNTASE INHIBITORS WITH TRAPPERS OF OXYGEN REACTIVE FORMS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-03-12 | — | — | WO | claimed |
| US-5476871-A | Method for the treatment of hypotension induced by a cytokine or bacterial endotoxin using s-alkyl- isothioureido-amino acids | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1995-12-19 | — | — | US | claimed |
| WO-1995013804-A1 | S-ALKYL-ISOTHIOUREIDO-AMINO ACIDS AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1995-05-26 | — | — | WO | claimed |
| US-5364881-A | S-alkyl-isothioureido-amino acids and use thereof | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1994-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, SMN1; SMN2 | NOS1 28/4885NOS2 17/4885NOS3 19/4885 |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, PYGB | NOS1 18/4885NOS2 13/4885NOS3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.